Search For
/
Stocks
Intraday Booster
Sector Booster
Stock Screener
Market Pulse
Screeners
More
Go Prime
My Plans
Privacy Policy
Contact
Refer & EarnScreenersMain
Stock Screener
Create Screener
Explore Screeners
Community ScreenersTrading Screeners
CandleSticks Screener
Top Gainers & Losers
Opening Range Breakout
Stock Screener AI
Stock Quality Scorecard
Overvalued StocksNewUndervalued StocksNewTechnical Screeners
NR4 Stocks
NR7 Stocks
Previous Day High Breakout
Previous Day Low Breakout
Previous Day Open Breakout
Bullish Crossover Stocks
Bearish Crossover Stocks
High Volume Shocker
VWAP Breakout Stocks
Range High Breakout
Range Low BreakoutMoreMarkets
Global Market Today
Global Indices
Indian Indices
NIfty TodaySmart Money
FII DII DataNew
FII Buying
NSE Insider Trading
SLB Stocks DataDerivatives
FnO Movements
NSE F&O Lot Size
Ban ListAnalysis & Calendars
Technical DashboardSector Booster
Sector AnalysisNew
Result Calendar
Economic Calendar
Cipla
Large Cap•27,764 Employees•IPO 1994
Current Price
₹1314.70
-9.6 (-0.72%)Updated
Today's Range
1301
₹1314.70
1327.5
52 Week Range
52W Low₹1281.70
52W High₹1673.00
₹1314.70
Downside2.57%
Upside27.25%
Price Chart
Compare with Peers
Historical Ratios
Track top 12 most important financial ratios
P/E Ratio: Price to Earnings - Most used valuation metric
Loading chart...
Analyzing Investment Quality
Processing 9 key metrics...
Key Metrics
Hover for details
Valuation
Market Cap
₹1,08,513.22 Cr
Market Cap
Total market value of companyP/E Ratio
23.87
P/E Ratio
Price to Earnings. Lower is generally better (<25 is good)P/B Ratio
3.69
P/B Ratio
Price to Book Value. <3 may indicate undervaluationEPS
₹56.26
EPS
Earnings Per Share. Higher and growing is positiveProfitability
ROE
8.03%
ROE
Return on Equity. >15% is good, >20% is excellentROCE
22.70%
ROCE
Return on Capital Employed. >15% is goodNet Margin
16.04%
Net Margin
Net profit as % of revenue. >10% is goodOperating Margin
-%
Operating Margin
Operating profit margin. >15% is goodGrowth
EPS Growth (5Y)
27.76%
EPS Growth (5Y)
5-year EPS growth. >15% is strongRevenue Growth (5Y)
9.97%
Revenue Growth (5Y)
5-year revenue growth. >10% is goodQtr Sales Growth
3.94%
Qtr Sales Growth
Quarter-over-quarter sales growthQtr Profit Growth
10.20%
Qtr Profit Growth
Quarter-over-quarter profit growthFinancial Health
Debt/Equity
0.01
Debt/Equity
Financial leverage. <1 is good, <0.5 is excellentBook Value
₹386.24
Book Value
Net asset value per shareDividend Yield
1.19%
Dividend Yield
Annual dividend as % of price. >2% is goodPromoter Holding
29.20%
Promoter Holding
Promoter stake. >50% shows confidenceGood
Average
Needs Attention
SWOT Analysis
Strengths
3 points- •Cipla boasts a robust ROE of 17.80%, signifying efficient shareholder investment management and strong earnings generation. This, coupled with a decent dividend yield of 0.82%, is attractive to income-seeking investors.
- •The company demonstrates strong profitability with a healthy OPM of 25.80% and a high ROCE of 22.70%, indicating efficient capital utilization and substantial returns on investments. Quarterly profit growth is also impressive at 10.20%.
Weaknesses
3 points- •Cipla's promoter holding of 29.20% is relatively low compared to industry peers, potentially raising concerns about corporate governance and long-term shareholding stability, which could impact stock price volatility.
- •Recent stock performance shows volatility, with a significant -2.59% change on October 30, 2025, and a -3.69% drop on October 24, 2025. This suggests susceptibility to market sentiment shifts and short-term price fluctuations.
Opportunities
3 points- •The pharmaceutical sector, where Cipla operates, is poised for growth driven by increasing global healthcare expenditure, an aging population, and the rising prevalence of chronic diseases, offering avenues for market expansion.
- •Cipla can capitalize on emerging markets and new therapeutic areas through strategic R&D investments and product diversification, potentially boosting its quarterly sales growth beyond the current 3.94%.
Threats
3 points- •Cipla faces intense competition from larger players like Sun Pharma (Market Cap ₹411,665 crore) and agile peers like Divi's Lab, which reported 26.74% quarterly profit growth, potentially impacting market share and pricing power.
- •The pharmaceutical industry is highly susceptible to stringent regulatory changes and increasing pricing pressure, especially in key markets, which could adversely affect Cipla's profitability and operational margins.
Segment-wise Financial Analysis
Fetching Financials...
Fetching Balance Sheet...
Fetching Cash Flow...
Shareholding Pattern
Loading shareholding data...
Company Insider Trading Activity
No insider trading data available
Corporate Action
Company Announcements
Technical Analysis & Indicators
Standard pivot points - most widely used
Pivot Points (CLASSIC)
| Level | Price | Distance | % Change |
|---|---|---|---|
| R4 | ₹1380.80 | +₹66.10 | +5.03% |
| R3 | ₹1354.30 | +₹39.60 | +3.01% |
| R2 | ₹1340.90 | +₹26.20 | +1.99% |
| R1 | ₹1327.80 | +₹13.10 | +1.00% |
| PIVOT | ₹1314.40 | -0.30 | -0.02% |
| CURRENT | ₹1314.70 | - | - |
| S1 | ₹1248.30 | -₹66.40 | -5.05% |
| S2 | ₹1274.80 | -₹39.90 | -3.03% |
| S3 | ₹1287.90 | -₹26.80 | -2.04% |
| S4 | ₹1301.30 | -₹13.40 | -1.02% |
CPR Levels
Support
Resistance
S4
N/A
S3
N/A
S2
N/A
S1
N/A
| CPR |
BC: N/AP: N/ATC: N/A
R1
N/A
R2
N/A
R3
N/A
R4
N/A
LTP: N/A
PDH: N/A
PDL: N/A
● Market Sentiment
is trading CPR, indicating
● CPR Width
CPR is
● Opening Range
Day's range: ~
● Price Position
Trading Inside opening range
Delivery Volume Analysis & Trading Activity
Latest Volume-10.8% vs avg
1.35M
(13 Mar 2026)Delivery %-2.7% vs avg
52.3%
(13 Mar 2026)Avg Volume (20D)20-day average
1.51M
(13 Feb - 13 Mar)Avg Delivery %Trend ↑
54.9%
(13 Feb - 13 Mar)Delivery % indicates the percentage of traded volume that resulted in actual delivery. Higher delivery % (>50%) suggests genuine buying interest and stronger hands.
Peer Comparison & Industry Benchmarking
Quick Compare
Largest by Market Cap
Sun Pharmaceutical Industries Ltd
4.12L ₹ Cr
Best Profit Growth
Laurus Labs Ltd
883.00 %
Highest Dividend Yield
Abbott India Ltd
1.79 %
Peer Comparison
| Company Name |
|---|
 Abbott India Ltd |
 Alkem Laboratories Ltd |
 Aurobindo Pharma Ltd |
 Dr Reddys Laboratories Ltd |
 Glenmark Pharmaceuticals Ltd |
 Laurus Labs Ltd |
 Lupin Ltd |
 Mankind Pharma Ltd |
 Sun Pharmaceutical Industries Ltd |
 Torrent Pharmaceuticals Ltd |
 Zydus Lifesciences Ltd |
About
Cipla Ltd
Cipla Limited is a multinational pharmaceutical company headquartered in Mumbai, India, with a global presence spanning the United States, South Africa, and other international markets. Established in 1935, the company's core business revolves around the manufacturing, development, sale, and distribution of a diverse range of pharmaceutical products.
Cipla operates primarily through two segments: Pharmaceuticals and New Ventures. The Pharmaceuticals segment forms the cornerstone of its business, encompassing the production and marketing of both generic and branded generic medications. This extensive portfolio covers a wide spectrum of therapeutic areas, addressing critical health concerns across numerous disease categories.
The company's product offerings are remarkably broad, including formulations and active pharmaceutical ingredients (APIs) targeting conditions such as myocardial infarction (MI), angina, heart disease, pulmonary illnesses, kidney failure, Alzheimer's disease, hypertension, arrhythmias, lipid abnormalities and diabetes, obesity, central nervous system disorders, HIV/AIDS, respiratory ailments including asthma, urological issues, oncology, cardio-metabolic diseases, pediatric health concerns, infectious diseases, critical care situations, hepatitis, women's health problems, ophthalmological conditions, and neuropsychiatric disorders. This comprehensive approach allows Cipla to cater to a vast patient population globally.
Beyond its core pharmaceutical business, Cipla is actively involved in several strategic growth areas under its New Ventures segment. This includes expansion into the consumer healthcare market, the development and commercialization of biosimilars (biologically similar medications), and the pursuit of opportunities within the specialty pharmaceutical sector. This diversification strategy positions Cipla for continued growth and expansion into high-value markets.
In summary, Cipla's business model is built upon a foundation of manufacturing and distributing a wide array of generic and branded generic pharmaceuticals across a multitude of therapeutic areas. Their strategic diversification into consumer healthcare, biosimilars, and specialty pharmaceuticals underscores their commitment to innovation and long-term growth within the global healthcare landscape.
COMPANY FACTS - CIPLA
Registered Address
Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel,
Mumbai
MAHARASHTRA
IN
Company Details
Group: Pharmaceuticals, Biotechnology & Life Sciences
Sector: Health Care
Industry: Pharmaceuticals
Exchange: NATIONAL STOCK EXCHANGE OF INDIA
Employees: 27,764
IPO Date: 03/11/1994
MANAGEMENT - CIPLA
Dr. Yusuf Hamied
Non-Executive Chairman of the Board
Mr. Umang Vohra
Global Chief Executive Officer, Managing Director, Executive Director
Mr. Ashish Adukia
Global Chief Financial Officer
Mr. Achin Gupta
Global Chief Operating Officer
Ms. Sneha Hiranandani
Chief Information Officer
Mr. Rajendra Chopra
Compliance Officer, Company Secretary
Mr. Rajeev Sinha
Global Chief Manufacturing Officer
Mr. Kamil Hamied
Non-Executive Director
Mr. Abhijit Joshi
Additional Non-Executive Director
Mr. Adil Zainulbhai
Additional Non-Executive Director
Ms. Maya Hari
Additional Independent Director
Dr. Balram Bhargava
Independent Non-Executive Director
Investor Questions Answered
Cipla Ltd (CIPLA) Stock FAQs
Get answers to the most common questions about Cipla Ltd stock price, fundamentals, financial metrics, and investment analysis
The current share price of Cipla Ltd (CIPLA) is ₹1,314.7. Today, the stock has declined by ₹9.60 (0.72%), trading in a range of ₹1,301 to ₹1,327.5. The stock opened at ₹1,324.3 with a trading volume of 13,46,347 shares.
Cipla Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹1,08,513.22 crores, P/E ratio of 23.87, ROE of 8.03%, and ROCE of 22.70%. The dividend yield stands at 1.19%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
The 52-week high price of Cipla Ltd (CIPLA) is ₹1,673, while the 52-week low is ₹1,281.7. Currently trading at ₹1,314.7, the stock is 8.4% away from its 52-week low and 21.4% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
Whether to buy Cipla Ltd stock at ₹1,314.7 depends on multiple factors. The stock is currently trading with a P/E ratio of 23.87 and P/B ratio of N/A. Today's performance shows a loss of 0.72%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
Cipla Ltd offers a dividend yield of 1.19%, which means for every ₹100 invested at the current price of ₹1,314.7, you can expect to receive approximately ₹1.19 annually as dividends. The face value of the stock is ₹2.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
Cipla Ltd's key financial metrics include: P/E Ratio: 23.87, P/B Ratio: N/A, ROE: 8.03%, ROCE: 22.70%, Dividend Yield: 1.19%, EPS: ₹56.26, Book Value: ₹386.24, Debt-to-Equity: 0.01, and Current Ratio: N/A. The company's market cap stands at ₹1,08,513.22 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
Cipla Ltd stock opened at ₹1,324.3 and is currently trading at ₹1,314.7, showing a decline of ₹9.60 (0.72%). The intraday high is ₹1,327.5 and low is ₹1,301. The trading volume stands at 13,46,347 shares, indicating strong market participation today.
Cipla Ltd has a Price-to-Earnings (P/E) ratio of 23.87, which means investors are willing to pay ₹23.87 for every ₹1 of earnings. With an EPS of ₹56.26, this P/E ratio indicates moderate valuation in line with market standards. Compare this with industry peers and historical P/E ratios for better context.
Cipla Ltd has a market capitalization of ₹1,08,513.22 crores, making it a large-cap company. Market cap is calculated by multiplying the current stock price (₹1,314.7) by the total number of outstanding shares. This metric helps investors understand the company's size, stability, and investment risk profile.
Cipla Ltd has a book value of ₹386.24 per share and a Price-to-Book (P/B) ratio of N/A. The current market price is ₹1,314.7, which is 240.4% above the book value. A P/B ratio below 1 may indicate undervaluation or asset quality concerns.
Cipla Ltd has a Return on Equity (ROE) of 8.03% and Return on Capital Employed (ROCE) of 22.70%. ROE measures how efficiently the company generates profits from shareholders' equity, while ROCE indicates how well the company uses its capital to generate profits. These returns may need improvement for better profitability. Higher percentages generally indicate better financial performance.
Cipla Ltd operates in the diversified sector and belongs to the general industry. The company competes with other players in this space and its performance is influenced by sector-specific trends, regulatory changes, and market dynamics. Understanding the sector helps investors assess growth potential, cyclical patterns, and industry-specific risks that may impact the stock's performance.
Cipla Ltd has a debt-to-equity ratio of 0.01, which measures the company's financial leverage by comparing total debt to shareholders' equity. A low ratio suggests conservative financing with minimal debt. Lower ratios generally indicate lower financial risk, but optimal levels vary by industry.
Cipla Ltd has an Earnings Per Share (EPS) of ₹56.26, which represents the company's profit allocated to each outstanding share. With a current stock price of ₹1,314.7 and P/E ratio of 23.87, investors are paying 23.87 times the annual earnings per share. This strong EPS indicates robust profitability. Track EPS growth over quarters to assess earnings momentum.
Cipla Ltd has reported a sales growth of N/A% and profit growth of N/A%. The company may be facing growth challenges or operating in a mature market. Consistent growth over multiple quarters is a positive indicator for long-term investors. Compare these growth rates with industry peers for better perspective.
Cipla Ltd has a current ratio of N/A, which measures the company's ability to pay short-term obligations with current assets. A ratio below 1 may indicate potential liquidity concerns. This metric is crucial for assessing the company's working capital management and financial safety.
To analyze Cipla Ltd stock, consider: 1) Fundamental Analysis - Review P/E (23.87), ROE (8.03%), debt-to-equity (0.01), and growth rates. 2) Technical Analysis - Check 52-week range (₹1281.70 - ₹1673.00), moving averages, and chart patterns. 3) Valuation - Compare current price (₹1314.70) with book value (₹386.24) and industry peers. 4) Financial Health - Assess current ratio (N/A) and cash flows. 5) Growth Prospects - Evaluate sales growth (N/A%) and profit growth (N/A%). Always diversify and consult a financial advisor.
The face value (or par value) of Cipla Ltd share is ₹2.00. Face value is the nominal value of a share as stated in the company's charter and is used for accounting purposes and calculating dividends. The current market price of ₹1,314.7 is 65635x the face value. Face value remains constant unless the company undergoes a stock split or bonus issue, while market price fluctuates based on demand and supply.
Investing in Cipla Ltd carries several risks: 1) Market Risk - Stock price volatility (52-week range: ₹1281.70 - ₹1673.00). 2) Business Risk - Industry-specific challenges in the sector. 3) Financial Risk - Debt-to-equity ratio of 0.01 indicates leverage. 4) Liquidity Risk - Based on trading volume of 13,46,347 shares. 5) Valuation Risk - P/E of 23.87 may indicate over/undervaluation. 6) Economic Risk - Macroeconomic factors affecting the industry. Diversify your portfolio and invest only what you can afford to lose.
Cipla Ltd operates in the industry with key metrics: P/E ratio of 23.87, ROE of 8.03%, market cap of ₹1,08,513.22 crores, and dividend yield of 1.19%. To make an informed comparison, analyze these metrics against industry peers considering factors like revenue growth (N/A%), profit margins, debt levels (D/E: 0.01), and market position. Use our peer comparison tool on this page to see detailed side-by-side analysis with competitors.
Target prices for Cipla Ltd vary among analysts and depend on multiple factors including earnings projections, industry trends, and market conditions. The stock is currently trading at ₹1,314.7, with a 52-week range of ₹1281.70 to ₹1673.00. Based on fundamentals like P/E (23.87), ROE (8.03%), and growth rates, analysts may have different target prices. Always refer to recent research reports from reputed brokerages and make decisions based on your own analysis and risk appetite.
Consider selling Cipla Ltd stock when: 1) Target Price Achieved - If the stock reaches your predetermined target from current ₹1314.70. 2) Fundamental Deterioration - Declining ROE (currently 8.03%), increasing debt (D/E: 0.01), or falling growth rates. 3) Better Opportunities - Finding stocks with superior risk-reward ratios. 4) Portfolio Rebalancing - When the stock becomes overweight in your portfolio. 5) Changed Investment Thesis - If reasons for buying no longer hold. 6) Stop Loss - If price falls below your risk threshold. Always base decisions on thorough analysis rather than emotions.
Tax implications for Cipla Ltd stock investments: 1) Short-term Capital Gains (STCG) - If sold within 1 year, gains taxed at 15% plus cess. 2) Long-term Capital Gains (LTCG) - If held over 1 year, gains above ₹1 lakh taxed at 10% without indexation. 3) Dividend Income - Dividends (current yield: 1.19%) are taxable as per your income tax slab. 4) Securities Transaction Tax (STT) - Applicable on both buy and sell transactions. 5) Intraday Trading - Treated as speculative income, taxed as per slab. Tax laws change periodically, so consult a tax advisor for personalized guidance and latest regulations.
Menu